182 related articles for article (PubMed ID: 33972251)
1. A Novel Running Wheel Mouse Model for Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy.
Schwartz A; Ben David A; Hotoveli M; Dor E; Diamant E; Vivyorka A; Rosen O; Torgeman A; Zichel R
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0042121. PubMed ID: 33972251
[TBL] [Abstract][Full Text] [Related]
2. A Novel Rabbit Spirometry Model of Type E Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy.
Diamant E; Pass A; Rosen O; Ben David A; Torgeman A; Barnea A; Tal A; Rosner A; Zichel R
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437616
[TBL] [Abstract][Full Text] [Related]
3. Studying the differential efficacy of postsymptom antitoxin treatment in type A versus type B botulism using a rabbit spirometry model.
Torgeman A; Schwartz A; Diamant E; Baruchi T; Dor E; Ben David A; Pass A; Barnea A; Tal A; Rosner A; Rosen O; Zichel R
Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30115749
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs.
Shi DY; Lu JS; Mao YY; Liu FJ; Wang R; Du P; Yu S; Yu YZ; Yang ZX
Appl Microbiol Biotechnol; 2023 May; 107(10):3205-3216. PubMed ID: 37058230
[TBL] [Abstract][Full Text] [Related]
5. Symptomatic treatment of botulism with a clinically approved small molecule.
Vazquez-Cintron E; Machamer J; Ondeck C; Pagarigan K; Winner B; Bodner P; Kelly K; Pennington MR; McNutt P
JCI Insight; 2020 Jan; 5(2):. PubMed ID: 31996484
[TBL] [Abstract][Full Text] [Related]
6. A Rabbit Model for the Evaluation of Drugs for Treating the Chronic Phase of Botulism.
Torgeman A; Diamant E; Dor E; Schwartz A; Baruchi T; Ben David A; Zichel R
Toxins (Basel); 2021 Sep; 13(10):. PubMed ID: 34678971
[TBL] [Abstract][Full Text] [Related]
7. A Monoclonal Antibody Combination against both Serotypes A and B Botulinum Toxin Prevents Inhalational Botulism in a Guinea Pig Model.
Snow DM; Cobb RR; Martinez J; Finger-Baker I; Collins L; Terpening S; Syar ES; Niemuth N; Kobs D; Barnewall R; Farr-Jones S; Marks JD; Tomic MT
Toxins (Basel); 2021 Jan; 13(1):. PubMed ID: 33466411
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing Concentrations of Anti-Botulinum Toxin Antibodies Positively Correlate with Mouse Neutralization Assay Results in a Guinea Pig Model.
Tomic MT; Farr-Jones S; Syar ES; Niemuth N; Kobs D; Hackett MJ; Espinoza Y; Martinez Z; Pham K; Snow DM; Marks JD; Cobb RR
Toxins (Basel); 2021 Sep; 13(9):. PubMed ID: 34564675
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of equine botulism antitoxin in botulism poisoning in a guinea pig model.
Emanuel A; Qiu H; Barker D; Takla T; Gillum K; Neimuth N; Kodihalli S
PLoS One; 2019; 14(1):e0209019. PubMed ID: 30633746
[TBL] [Abstract][Full Text] [Related]
10. Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E.
Shi DY; Liu FJ; Mao YY; Cui RT; Lu JS; Yu YZ; Dong XJ; Yang ZX; Sun ZW; Pang XB
Hum Vaccin Immunother; 2020; 16(1):100-108. PubMed ID: 31210561
[TBL] [Abstract][Full Text] [Related]
11. A cell-based alternative to the mouse potency assay for pharmaceutical type E botulinum antitoxins.
Diamant E; Torgeman A; Epstein E; Mechaly A; David AB; Levin L; Schwartz A; Dor E; Girshengorn M; Barnea A; Mazor O; Zichel R
ALTEX; 2022; 39(1):113-122. PubMed ID: 34798660
[TBL] [Abstract][Full Text] [Related]
12. Development and preclinical evaluation of a new F(ab')₂ antitoxin against botulinum neurotoxin serotype A.
Yu YZ; Zhang SM; Wang WB; Du Y; Zhu HQ; Wang RL; Zhou XW; Lin JB; Wang S; Yu WY; Huang PT; Sun ZW
Biochimie; 2010 Oct; 92(10):1315-20. PubMed ID: 20600570
[TBL] [Abstract][Full Text] [Related]
13. Antidotal treatment of botulism in rats by continuous infusion with 3,4-diaminopyridine.
Machamer JB; Vazquez-Cintron EJ; O'Brien SW; Kelly KE; Altvater AC; Pagarigan KT; Dubee PB; Ondeck CA; McNutt PM
Mol Med; 2022 Jun; 28(1):61. PubMed ID: 35659174
[TBL] [Abstract][Full Text] [Related]
14. Iatrogenic Botulism: A Case Treated With Botulinum Antitoxin.
Gonul Oner O; Gudek HC; Erturk Cetin O; Demir S
Clin Neuropharmacol; 2023 Mar-Apr 01; 46(2):82-84. PubMed ID: 36728838
[TBL] [Abstract][Full Text] [Related]
15. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.
Fan Y; Barash JR; Lou J; Conrad F; Marks JD; Arnon SS
J Infect Dis; 2016 May; 213(10):1606-14. PubMed ID: 26936913
[TBL] [Abstract][Full Text] [Related]
16. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model.
Mukherjee J; Tremblay JM; Leysath CE; Ofori K; Baldwin K; Feng X; Bedenice D; Webb RP; Wright PM; Smith LA; Tzipori S; Shoemaker CB
PLoS One; 2012; 7(1):e29941. PubMed ID: 22238680
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model.
Tomic MT; Espinoza Y; Martinez Z; Pham K; Cobb RR; Snow DM; Earnhart CG; Pals T; Syar ES; Niemuth N; Kobs DJ; Farr-Jones S; Marks JD
Toxins (Basel); 2019 Apr; 11(4):. PubMed ID: 30959899
[TBL] [Abstract][Full Text] [Related]
18. A human bispecific antibody neutralizes botulinum neurotoxin serotype A.
Lu J; Jiang Y; Guo J; Chen L; Liu F; Li Z; Liu X; Du P; Yu Y; Wang R; Yang Z
Sci Rep; 2023 Nov; 13(1):20806. PubMed ID: 38012220
[TBL] [Abstract][Full Text] [Related]
19. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins.
Barash JR; Arnon SS
J Infect Dis; 2014 Jan; 209(2):183-91. PubMed ID: 24106296
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of equine botulism antitoxin in Rhesus macaques.
Kodihalli S; Emanuel A; Takla T; Hua Y; Hobbs C; LeClaire R; O'Donnell DC
PLoS One; 2017; 12(11):e0186892. PubMed ID: 29166654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
